Glecaprevir
drugOn this page
Also known as A-1282576A-1282576.0A-12825760ABT-493Glecaprevir component of mavyret
Summary
Glecaprevir (CHEMBL3545363) is an approved small molecule; indicated across 6 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 50
- Chemistry: 838.9 Da · C38H46F4N6O9S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545363 |
| Name | Glecaprevir |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 66828839 |
| Molecular formula | C38H46F4N6O9S |
| Molecular weight | 838.9 |
| InChIKey | MLSQGNCUYAMAHD-ITNVBOSISA-N |
SMILES: CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
IUPAC name: (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
Also known as: A-1282576, A-1282576.0, A-12825760, ABT-493, Glecaprevir, Glecaprevir component of mavyret, GLECAPREVIR
Patent coverage: 298 distinct patent families (654 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 597 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis C virus infection | 4 | MONDO:0005354 | EFO:0004220 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| post-traumatic stress disorder | 2 | MONDO:0005146 | EFO:0001358 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| chronic kidney disease | 0 | MONDO:0005300 | EFO:0003884 |
Clinical trials
Total trials: 50.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 21 |
| PHASE4 | 9 |
| PHASE2/PHASE3 | 6 |
| Not specified | 6 |
| PHASE2 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03623568 | PHASE4 | WITHDRAWN | Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant |
| NCT03627299 | PHASE4 | COMPLETED | Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors |
| NCT03781726 | PHASE4 | COMPLETED | Multi-center Study to Transplant Hepatitis-C Infected Kidneys |
| NCT03855917 | PHASE4 | UNKNOWN | Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
| NCT04235049 | PHASE4 | WITHDRAWN | Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) |
| NCT04515797 | PHASE4 | TERMINATED | QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
| NCT04575896 | PHASE4 | COMPLETED | Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
| NCT04614142 | PHASE4 | WITHDRAWN | Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access |
| NCT05582681 | PHASE4 | TERMINATED | HCV Test and Treat Utilizing Simplified HCV Patient Education |
| NCT05637879 | PHASE2/PHASE3 | RECRUITING | Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
| NCT02243293 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection |
| NCT02441283 | PHASE2/PHASE3 | COMPLETED | A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 |
| NCT02446717 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy |
| NCT02604017 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection |
| NCT02634008 | PHASE3 | COMPLETED | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P |
| NCT02636595 | PHASE3 | COMPLETED | The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) |
| NCT02640157 | PHASE3 | COMPLETED | A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection |
| NCT02640482 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection |
| NCT02642432 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis |
| NCT02651194 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection |
| NCT02692703 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) |
| NCT02707952 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection |
| NCT02723084 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection |
| NCT02939989 | PHASE3 | COMPLETED | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study |
| NCT02966795 | PHASE3 | COMPLETED | A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
| NCT03067129 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection |
| NCT03069365 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment |
| NCT03089944 | PHASE3 | COMPLETED | A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis |
| NCT03092375 | PHASE3 | COMPLETED | Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects |
| NCT03117569 | PHASE3 | COMPLETED | Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients |
| NCT03212521 | PHASE3 | COMPLETED | Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 |
| NCT03219216 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection |
| NCT03222583 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection |
| NCT03235349 | PHASE3 | COMPLETED | Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection |
| NCT04903626 | PHASE3 | COMPLETED | Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
| NCT05446857 | PHASE2/PHASE3 | COMPLETED | Glecaprevir/Pibrentasvir for the Treatment of PTSD |
| NCT07040319 | PHASE1/PHASE2 | RECRUITING | Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV |
| NCT01995071 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) |
| NCT02243280 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection |
| NCT04042740 | PHASE2 | COMPLETED | Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).